Based on recommendations from the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW)26, molecular testing to assess for EGFR amplification, chromosome 7 gain/chromosome 10 loss, and TERT promoter mutations to diagnose a diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV could have been performed to predict increased biological aggression and perhaps tailor clinical management27,28. The gene discussed is EGFR; the disease is central nervous system neoplasm.